A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Sep 2017
At a glance
- Drugs Fostamatinib (Primary)
- Indications IgA nephropathy
- Focus Therapeutic Use
- Acronyms SIGN
- Sponsors Rigel Pharmaceuticals
- 01 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Mar 2018.
- 01 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Feb 2018.
- 01 Aug 2017 Status changed from recruiting to active, no longer recruiting.